Ma Yingli (CIK 1963664) reported 6 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-03-23). Recent activity: Buy GPCR (32,526 shares), Sell GPCR (11,313 shares), Sell GPCR (4,470 shares), Sell GPCR (1,824 shares), Buy GPCR (24,459 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Buy | 32,526 | $0 |
| 2026-03-05 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Sell | 11,313 | $237,460 |
| 2025-08-20 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Sell | 4,470 | $30,575 |
| 2025-07-03 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Sell | 1,824 | $14,446 |
| 2025-07-03 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Buy | 24,459 | $0 |
| 2025-03-18 | Structure Therapeutics Inc. (GPCR) | CHIEF TECHNOLOGY OFFICER | Buy | 63,810 | $0 |
Source: SEC Form 4 filings · as of 2026-03-23